

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

**SCHEDULE 13G/A**

UNDER THE SECURITIES EXCHANGE ACT OF 1934

---

**Nautilus Biotechnology, Inc.**

(Name of Issuer)

COMMON STOCK, \$0.0001 PAR VALUE PER SHARE  
(Title of Class of Securities)

63909J 108

(CUSIP Number)

June 9, 2021

(Date of Event Which Requires Filing of this Statement)

---

Check the Appropriate Box to Designate the Rule Pursuant to Which this Schedule Is Filed:

- Rule 13d-1(b)
- Rule13d-1(c)
- Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

---

---

<b>1</b>	<b>NAMES OF REPORTING PERSONS</b> ARYA Sciences Holdings III	
<b>2</b>	<b>CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP</b> (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
<b>3</b>	<b>SEC USE ONLY</b>	
<b>4</b>	<b>CITIZENSHIP OR PLACE OF ORGANIZATION</b> Cayman Islands	
<b>NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH</b>	<b>5</b>	<b>SOLE VOTING POWER</b> 4,146,500 <sup>(1)</sup>
	<b>6</b>	<b>SHARED VOTING POWER</b> 0
	<b>7</b>	<b>SOLE DISPOSITIVE POWER</b> 4,146,500 <sup>(1)</sup>
	<b>8</b>	<b>SHARED DISPOSITIVE POWER</b> 0
<b>9</b>	<b>AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON</b> 4,146,500 <sup>(1)</sup>	
<b>10</b>	<b>CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)</b> <input type="checkbox"/>	
<b>11</b>	<b>PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)</b> 3.3% <sup>(1)(2)</sup>	
<b>12</b>	<b>TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)</b> CO	

<b>1</b>	<b>NAMES OF REPORTING PERSONS</b> Adam Stone	
<b>2</b>	<b>CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP</b> (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
<b>3</b>	<b>SEC USE ONLY</b>	
<b>4</b>	<b>CITIZENSHIP OR PLACE OF ORGANIZATION</b> United States	
<b>NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH</b>	<b>5</b>	<b>SOLE VOTING POWER</b> 0
	<b>6</b>	<b>SHARED VOTING POWER</b> 4,146,500 <sup>(1)</sup>
	<b>7</b>	<b>SOLE DISPOSITIVE POWER</b> 0
	<b>8</b>	<b>SHARED DISPOSITIVE POWER</b> 4,146,500 <sup>(1)</sup>
<b>9</b>	<b>AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON</b> 4,146,500 <sup>(1)</sup>	
<b>10</b>	<b>CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)</b> <input type="checkbox"/>	
<b>11</b>	<b>PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)</b> 3.3% <sup>(1)(2)</sup>	
<b>12</b>	<b>TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)</b> IN	

<b>1</b>	<b>NAMES OF REPORTING PERSONS</b> Michael Altman	
<b>2</b>	<b>CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP</b> (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
<b>3</b>	<b>SEC USE ONLY</b>	
<b>4</b>	<b>CITIZENSHIP OR PLACE OF ORGANIZATION</b> United States	
<b>NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH</b>	<b>5</b>	<b>SOLE VOTING POWER</b> 0
	<b>6</b>	<b>SHARED VOTING POWER</b> 4,146,500 <sup>(1)</sup>
	<b>7</b>	<b>SOLE DISPOSITIVE POWER</b> 0
	<b>8</b>	<b>SHARED DISPOSITIVE POWER</b> 4,146,500 <sup>(1)</sup>
<b>9</b>	<b>AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON</b> 4,146,500 <sup>(1)</sup>	
<b>10</b>	<b>CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)</b> <input type="checkbox"/>	
<b>11</b>	<b>PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)</b> 3.3% <sup>(1)(2)</sup>	
<b>12</b>	<b>TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)</b> IN	

(1) See Item 4. Represents 4,146,500 shares of common stock of the Issuer.

(2) Based on 124,045,255 shares of common stock of the Issuer issued and outstanding as of the date of this Amendment.

## Schedule 13D/A

ARYA Sciences Holdings III (the “Sponsor”), Adam Stone and Michael Altman (together, the “Reporting Persons”) are filing this Amendment No. 1 (the “Amendment”) to amend and supplement the Statement on Schedule 13D relating to the ordinary shares, \$0.0001 par value per share of ARYA Sciences Acquisition Corp III (“ARYA”), filed by the Reporting Persons with the SEC on February 16, 2021 (the “Sponsor Schedule 13D”). Capitalized terms not defined herein have the meanings given to such terms in the Sponsor Schedule 13D. Except as set forth herein, the Sponsor Schedule 13D is unmodified.

**Item 1(a) Name of Issuer**

Nautilus Biotechnology, Inc. (the “Issuer”)

**Item 1(b) Address of the Issuer’s Principal Executive Offices**

425 Pontius Ave N, Ste 202  
Seattle, WA 98109

**Item 2(d) Title of Class of Securities**

Common Stock, \$0.0001 par value per share.

**Item 2(e) CUSIP Number**

63909J 108

**Item 4. Ownership**

The information contained in Item 4 of the Sponsor Schedule 13D is hereby amended and supplemented by adding the following at the end thereof.

As of June 9, 2021, the Reporting Persons hold 4,146,500 shares of common stock of the Issuer, representing 3.3% of the issued and outstanding shares of common stock of the Issuer. In connection with the Business Combination Agreement, dated February 7, 2021, by and among ARYA, Mako Merger Sub, Inc. and Nautilus Biotechnology, Inc., ARYA domesticated as a Delaware corporation (the “Domestication”) and changed its name to “Nautilus Biotechnology, Inc.” In connection with the Domestication, the Sponsor’s 3,647,500 Class B ordinary shares, par value \$0.0001 per share, of ARYA, which were previously convertible into Class A ordinary shares of ARYA, were automatically converted into shares of common stock of the Issuer, par value \$0.0001 per share, on a one-for-one basis. Further, the Sponsor’s 499,999 private placement shares, par value \$0.0001 per share, of ARYA automatically converted into shares of common stock of the Issuer, par value \$0.0001 per share, on a one-for-one basis.

**Item 5. Ownership of Five Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Amendment is true, complete and correct.

**DATE:** June 11, 2021

**Arya Sciences Holdings III**

By: /s/ Samuel Cohn

Name: Samuel Cohn

Title: Secretary

/s/ Adam Stone

**Adam Stone**

/s/ Michael Altman

**Michael Altman**

## Exhibit Index

<b>Exhibit No.</b>	<b>Description</b>
<a href="#">Exhibit 99.1</a>	Joint Filing Agreement, dated as of June 11, 2021, by and among ARYA Sciences Holdings III, Adam Stone and Michael Altman.

**Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations  
(See 18 U.S.C. 1001)**

---

**EXHIBIT 99.1**

**JOINT FILING AGREEMENT**

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G/A (including any and all amendments thereto) with respect to the shares of common stock, \$0.0001 par value per share, of Nautilus Biotechnology, Inc., and further agree that this Joint Filing Agreement shall be included as an exhibit to such joint filings.

The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13G/A and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.

This Joint Filing Agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the same instrument.

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of June 11, 2021.

**Arya Sciences Holdings III**

By: /s/ Samuel Cohn

Name: Samuel Cohn

Title: Secretary

/s/ Adam Stone

**Adam Stone**

/s/ Michael Altman

**Michael Altman**

---